Moreover, since DNA methylation is a reversible epigenetic mark, THOR hypermethylation is a potential therapeutic target for BC treatment, in particular for BC subtypes whose available therapies are not truly effective, such as TNBC and metastatic BC [52]. Here, THORLNC is linked to breast cancer.